Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 126

Sort by

Sort Order Select

Journal Articles

Outcomes of Patients with Acute Myeloid Leukemia with Myelodysplastic Are Dependent on Diagnostic Criteria and Therapy

Guillermo Montalban-Bravo, MD, Rashmi Kanagal-Shamanna, MD, Koji Sasaki, MD, Farhad Ravandi, MD, Jorge E. Cortes, MD, Naval G. Daver, MD, Koichi Takahashi, MD, Courtney D. DiNardo, MD MSc, Elias Jabbour, MD, Gautam M. Borthakur, MD, Kiran Naqvi, MDMPH, Marina Y Konopleva, MD PhD, Sherry A. Pierce, BSN, BA, Carlos E. Bueso-Ramos, MD PhD, Keyur P. Patel, MBBS, PhD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD, Tapan M. Kadia, MD

Blood (2019) 134 (Supplement_1): 647.

https://doi.org/10.1182/blood-2019-129373

Published: 2019

Journal Articles

Outcomes of Patients with Acute Myeloid Leukemia (AML) with Myelodysplasia Related Changes (AML-MRC) Are Dependent on Diagnostic Criteria and Therapy

Guillermo Montalban Bravo, MD, Rashmi Kanagal-Shamanna, MD, Koji Sasaki, MD, Farhad Ravandi, MD, Jorge E. Cortes, MD, Naval G. Daver, MD, Koichi Takahashi, MD, Courtney D. DiNardo, MDMSc, Elias Jabbour, MD, Gautam M. Borthakur, MD, Kiran Naqvi, MDMPH, Marina Y Konopleva, MD PhD, Sherry A. Pierce, BSN, BA, Carlos E. Bueso-Ramos, MD PhD, Keyur P. Patel, MBBS, PhD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD, Tapan M. Kadia, MD

Blood (2019) 134 (Supplement_1): 1312.

https://doi.org/10.1182/blood-2019-131998

Published: 2019

Journal Articles

CUL1: Novel Therapeutic Target in Myeloid Neoplasms Harboring -7/Del(7q)

Blood (2019) 134 (Supplement_1): 1281.

https://doi.org/10.1182/blood-2019-129196

Published: 2019

Journal Articles

A Multi-Omic Precision Medicine Clinical Trial in Acute Leukemia

Blood (2019) 134 (Supplement_1): 1269.

https://doi.org/10.1182/blood-2019-130996

Published: 2019

Journal Articles

Phase 2 Study of E7777, a Diphtheria Toxin Fragment-Interleukin-2 Fusion Protein, in Japanese Patients with Relapsed or Refractory Peripheral and Cutaneous T-Cell Lymphoma

Blood (2019) 134 (Supplement_1): 4032.

https://doi.org/10.1182/blood-2019-121723

Published: 2019

Journal Articles

Cryo-EM Structure of BIVV001 Reveals Coagulation Factor VIII-Von Willebrand Factor D'D3 Interaction Mode

James Fuller, PhD, Joseph Batchelor, PhD, Kevin Knockenhauer, PhD, Hans-Peter Biemann, PhD, Robert Peters

Blood (2019) 134 (Supplement_1): 94.

https://doi.org/10.1182/blood-2019-126645

Published: 2019

Journal Articles

A Feasibility Study of Biologically Focused Therapy for Myelodysplastic Syndrome Patients Refractory to Hypomethylating Agents

Michael A Spinner, Alexey Aleshin, MD MBA, Marianne A Santaguida, PhD, Steven A Schaffert, PhD, Taher Abbasi, MS, MBA, Jeffrey N Sanders, A Scott Patterson, MA, Diane Heiser, PhD, James L Zehnder, Peter L Greenberg, MD

Blood (2019) 134 (Supplement_1): 4239.

https://doi.org/10.1182/blood-2019-129473

Published: 2019

Journal Articles

Disease and Clinical Characteristics of Patients with Myelofibrosis Enrolled in the MOST Study

Aaron T. Gerds, MD MS, Roger M. Lyons, MD, Philomena Colucci, DO, MS, Patricia Kalafut, PhD, Dilan Paranagama, PhD, Srdan Verstovsek, MD PhD

Blood (2019) 134 (Supplement_1): 4190.

https://doi.org/10.1182/blood-2019-122441

Published: 2019

Journal Articles

Changing the Natural History of Fanconi Anemia Complementation Group-A with Gene Therapy: Early Results of U.S. Phase I Study of Lentiviral-Mediated Ex-Vivo FANCA Gene Insertion in Human Stem and Progenitor Cells

Agnieszka Czechowicz, MD PhD, Maria Grazia Roncarolo, MD, Brian C Beard, PhD, Ken Law, PhD, Eileen Nicoletti, MD, Paula Río, PhD, Juan A. Bueren, PhD, Jonathan D Schwartz, MD, Sandeep Soni, MBBS

Blood (2019) 134 (Supplement_1): 3350.

https://doi.org/10.1182/blood-2019-127352

Published: 2019

Journal Articles

Prognostic Impact of Time from Diagnosis to Initial Chemotherapy for Acute Myeloid Leukemia

Yoshimasa Kamoda, MD, Akira Hangaishi, MD PhD, Hiroki Hayashida, MD, Yusuke Uchibori, MD, Hiromitsu Iizuka, MD PhD, Michiko Kida, MD PhD, Kensuke Usuki, MD PhD

Blood (2018) 132 (Supplement 1): 3981.

https://doi.org/10.1182/blood-2018-99-111123

Published: 2018

Journal Articles

Single-Cell Analysis of the Transcriptional Response in AML Patients Treated with BET-Inhibitors

Sophia Miliara, BSc, MSc, PhD, Bogumil Kaczkowski, PhD, Takahiro Suzuki, PhD, Huthayfa Mujahed, MSc, Maasaki Furuno, PhD, Satoshi Takizawa, Harukazu Suzuki, PhD, Takahiro Arakawa, Soren Lehmann, MD PhD, Andreas Lennartsson, PhD, Erik Arner, PhD

Blood (2018) 132 (Supplement 1): 5120.

https://doi.org/10.1182/blood-2018-99-117849

Published: 2018

Journal Articles

Disease and Clinical Characteristics of Patients with Essential Thrombocythemia Enrolled in the MOST Study

Abdulraheem Yacoub, MD, Roger M. Lyons, MD, Srdan Verstovsek, MD PhD, Ryan Shao, MD, David Tin Chu, MD, Apurv Agrawal, MD, Smitha Sivaraman, PhD, Philomena Colucci, DO, MS, Peter Yao, John Mascarenhas, MD

Blood (2018) 132 (Supplement 1): 4306.

https://doi.org/10.1182/blood-2018-99-112183

Published: 2018

Journal Articles

In-Vitro Drug Sensitivity Screening in Chronic Lymphocytic Leukemia (CLL) Primary Patient Samples Identifies Drug Candidates for Precision Cancer Therapy

Deepak Balaji balaji Thimiri Govinda Raj, PhD MSc, Andrea Cremaschi, PhD MSc, Sigrid Strand Skånland, PhD, Alexandra Gade, Fredrik H. Schjesvold, MD PhD, Geir Erland Tjønnfjord, MD DMsc, Ludvig A Munthe, Kjetil Tasken

Blood (2018) 132 (Supplement 1): 4676.

https://doi.org/10.1182/blood-2018-99-110357

Published: 2018

Journal Articles

Phase 3 Study of Lenalidomide (LEN) Vs Placebo in Non-Transfusion Dependent (TD) Low Risk Del(5q) MDS Patients with Del(5q) — Preliminary Blinded Analysis of the European Sintra-REV Trial

Blood (2018) 132 (Supplement 1): 468.

https://doi.org/10.1182/blood-2018-99-119430

Published: 2018

Journal Articles

Impact of Inotersen on Functioning and Activities of Daily Living for Patients with Hereditary TTR Amyloidosis: Results from a Double-Blind Placebo-Controlled Trial

Aaron Yarlas, PhD, Giampaolo Merlini, MD, Michelle K White, PhD, Asia Sikora Kessler, PhD, Andrew Lovley, MA, Spencer D Guthrie, MPH, MBA, Michael Pollock, Morie A. Gertz, MD

Blood (2018) 132 (Supplement 1): 4812.

https://doi.org/10.1182/blood-2018-99-119578

Published: 2018

Journal Articles

Impact of Inotersen on Subgroups of Patients with Hereditary TTR Amyloidosis: Results from a Double-Blind Placebo-Controlled Trial

Aaron Yarlas, PhD, Giampaolo Merlini, MD, Michelle K White, PhD, Asia Sikora Kessler, PhD, Andrew Lovley, MA, Spencer D Guthrie, MPH, MBA, Michael Pollock, Morie A. Gertz, MD

Blood (2018) 132 (Supplement 1): 4803.

https://doi.org/10.1182/blood-2018-99-119216

Published: 2018

Journal Articles

Combining Next Generation Proteomics Platforms with Drug Sensitivity Resistance Testing AllowsÂ Identification of Physiologically Distinct Sub-ClonesÂ That Can Inform Therapeutic and Drug Development Strategies

Despina Bazou, BSc, MSc, PhD, Muntasir M Majumder, MSc, BPharm, Ciara Tierney, BSc, Sinead O'Rourke, BSc, Pekka Anttila, MD, Raija Helena Silvennoinen, MD PhD, Caroline A Heckman, PhD, Paul Dowling, BSc, PhD, Peter O'Gorman, MD PhD FRCP, FRCPath

Blood (2018) 132 (Supplement 1): 1901.

https://doi.org/10.1182/blood-2018-99-115910

Published: 2018

Journal Articles

KRX-101, a Novel FLT3 Inhibitor, Potently Active Against Resistant FLT3 -ITD/ FLT3 -TKD Mutant AML in Vitro and In Vivo

Herman O Sintim, PhD, M. Javad Aman, PhD, Frederick Holtsberg, PhD, Ashkan Emadi, MD PhD, Rena G Lapidus, PhD

Blood (2018) 132 (Supplement 1): 4049.

https://doi.org/10.1182/blood-2018-99-115260

Published: 2018

Journal Articles

Outcomes of Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Included in Phase I Clinical Trials

Marion Brault, Maxime Annereau, PharmD, Alina Danu, MD, Julien Lazarovici, MD, Claude Chahine, MD, Andrea Varga, Capucine Baldini, Stéphane Champiat, Malik Berhoune, Christophe Massard, François Lemare, Vincent Ribrag, MD, Jean-Marie Michot, MD

Blood (2018) 132 (Supplement 1): 2992.

https://doi.org/10.1182/blood-2018-99-112919

Published: 2018

Journal Articles

Updated Report of a Phase I/II Multicenter Study of Forodesine, a Purine Nucleoside Phosphorylase Inhibitor, in Japanese Patients with Relapsed Peripheral T-Cell Lymphoma

Blood (2017) 130 (Supplement 1): 4075.

https://doi.org/10.1182/blood.V130.Suppl_1.4075.4075

Published: 2017

NARROW

Outcomes of Patients with Acute Myeloid Leukemia with Myelodysplastic Are Dependent on Diagnostic Criteria and Therapy

Outcomes of Patients with Acute Myeloid Leukemia (AML) with Myelodysplasia Related Changes (AML-MRC) Are Dependent on Diagnostic Criteria and Therapy

CUL1: Novel Therapeutic Target in Myeloid Neoplasms Harboring -7/Del(7q)

A Multi-Omic Precision Medicine Clinical Trial in Acute Leukemia

Phase 2 Study of E7777, a Diphtheria Toxin Fragment-Interleukin-2 Fusion Protein, in Japanese Patients with Relapsed or Refractory Peripheral and Cutaneous T-Cell Lymphoma

Cryo-EM Structure of BIVV001 Reveals Coagulation Factor VIII-Von Willebrand Factor D'D3 Interaction Mode

A Feasibility Study of Biologically Focused Therapy for Myelodysplastic Syndrome Patients Refractory to Hypomethylating Agents

Disease and Clinical Characteristics of Patients with Myelofibrosis Enrolled in the MOST Study

Changing the Natural History of Fanconi Anemia Complementation Group-A with Gene Therapy: Early Results of U.S. Phase I Study of Lentiviral-Mediated Ex-Vivo FANCA Gene Insertion in Human Stem and Progenitor Cells

Prognostic Impact of Time from Diagnosis to Initial Chemotherapy for Acute Myeloid Leukemia

Single-Cell Analysis of the Transcriptional Response in AML Patients Treated with BET-Inhibitors

Disease and Clinical Characteristics of Patients with Essential Thrombocythemia Enrolled in the MOST Study

In-Vitro Drug Sensitivity Screening in Chronic Lymphocytic Leukemia (CLL) Primary Patient Samples Identifies Drug Candidates for Precision Cancer Therapy

Phase 3 Study of Lenalidomide (LEN) Vs Placebo in Non-Transfusion Dependent (TD) Low Risk Del(5q) MDS Patients with Del(5q) — Preliminary Blinded Analysis of the European Sintra-REV Trial

Impact of Inotersen on Functioning and Activities of Daily Living for Patients with Hereditary TTR Amyloidosis: Results from a Double-Blind Placebo-Controlled Trial

Impact of Inotersen on Subgroups of Patients with Hereditary TTR Amyloidosis: Results from a Double-Blind Placebo-Controlled Trial

Combining Next Generation Proteomics Platforms with Drug Sensitivity Resistance Testing AllowsÂ Identification of Physiologically Distinct Sub-ClonesÂ That Can Inform Therapeutic and Drug Development Strategies

KRX-101, a Novel FLT3 Inhibitor, Potently Active Against Resistant FLT3 -ITD/ FLT3 -TKD Mutant AML in Vitro and In Vivo

Outcomes of Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Included in Phase I Clinical Trials

Updated Report of a Phase I/II Multicenter Study of Forodesine, a Purine Nucleoside Phosphorylase Inhibitor, in Japanese Patients with Relapsed Peripheral T-Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only